InvestorsHub Logo
Followers 829
Posts 119608
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Tuesday, 11/03/2020 8:54:33 AM

Tuesday, November 03, 2020 8:54:33 AM

Post# of 1162
BMY’s Deucravacitinib bests AMGN’s Otezla_in_phase-3_psoriasis_study:

https://www.businesswire.com/news/home/20201103005189/en/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla%C2%AE-apremilast-in-Pivotal-Phase-3-Psoriasis-Study

Deucravacitinib (f/k/a BMS-986165) is an oral TYK2 inhibitor.

Otezla is the drug BMY sold to AMGN for $13.4B to satisfy regulatory requirements for the CELG acquisition (#msg-150752130)—a decision that now looks even better.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News